The Delivery of High-Dose Dry Powder Antibiotics by a Low-Cost Generic Inhaler.
The routine of loading multiple capsules for delivery of high-dose antibiotics is time consuming, which may reduce patient adherence to inhaled treatment. To overcome this limitation, an investigation was carried out using four modified versions of the Aerolizer® that accommodate a size 0 capsule for delivery of high payload formulations. In some prototypes, four piercing pins of 0.6 mm each were replaced with a single centrally located 1.2-mm pin and one-third reduced air inlet of the original design. The performance of these inhalers was evaluated using spray-dried antibiotic powders with distinct morphologies: spherical particles with a highly corrugated surface (colistin and tobramycin) and needle-like particles (rifapentine). The inhalers were tested at capsule loadings of 50 mg (colistin), 30 mg (rifapentine) and 100 mg (tobramycin) using a multistage liquid impinger (MSLI) operating at 60 L/min. The device with a single pin and reduced air inlet showed a superior performance than the other prototypes in dispersing colistin and rifapentine powders, with a fine particle fraction (FPF wt% <5 μm in the aerosol) between 62 and 68%. Subsequently, an Aerolizer® with the same configuration (single pin and one-third air inlet) that accommodates a size 00 capsule was designed to increase the payload of colistin and rifapentine. The performance of the device at various inspiratory flow rates and air volumes achievable by most cystic fibrosis (CF) patients was examined at the maximum capsule loading of 100 mg. The device showed optimal performance at 45 L/min with an air volume of 1.5-2.0 L for colistin and 60 L/min with an air volume of 2.0 L for rifapentine. In conclusion, the modified size 00 Aerolizer® inhaler as a low-cost generic device demonstrated promising results for delivery of various high-dose formulations for treatment of lung infections.
Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, NSW, 2006, Australia.
Thaigarajan
T
Parumasivam
Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, NSW, 2006, Australia.
Sharon S Y
SS
Leung
Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, NSW, 2006, Australia.
Patricia
P
Tang
R & D and Industrialization, Plastiape S.p.A., 23875, Osnago, Italy.
Citterio
C
Mauro
Tuberculosis Research Program, Centenary Institute, The University of Sydney, Sydney, NSW, 2006, Australia.|Infectious Diseases and Immunology, Sydney Medical School, The University of Sydney, Sydney, NSW, 2006, Australia.
Warwick
W
Britton
Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, NSW, 2006, Australia. kim.chan@sydney.edu.au.
Hak-Kim
HK
Chan
D000280:Administration, Inhalation; D000336:Aerosols; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000737:chemistry; D003362:Cost-Benefit Analysis; D004305:Dose-Response Relationship, Drug; D016503:Drug Delivery Systems / Q000191:economics / Q000295:instrumentation*; D058995:Dry Powder Inhalers / Q000191:economics / Q000379:methods*; D004867:Equipment Design; D006801:Humans; D010316:Particle Size; D011208:Powders; D013499:Surface Properties
D000336:Aerosols; D000900:Anti-Bacterial Agents; D011208:Powders
aerosolisation; dry powder inhaler; high-dose delivery; lung infection; modified Aerolizer®
AAPS J. 2012 Sep;14(3):400-9
22476943
Breathe (Sheff). 2015 Jun;11(2):110-8
26306111
Drug Dev Ind Pharm. 2015 May;41(5):859-65
24811055
J Aerosol Med. 2006 Winter;19(4):456-65
17196074
AAPS J. 2013 Apr;15(2):511-22
23371759
Caspian J Intern Med. 2014 Summer;5(3):130-6
25202439
Int J Pharm. 2010 Nov 30;401(1-2):1-6
20699113
Arerugi. 2014 Dec;63(10):1325-9
25634457
J Intensive Care. 2015 Jan 22;3(1):3
25705428
Pharm Res. 1991 Sep;8(9):1159-65
1788162
Treat Respir Med. 2004;3(1):35-44
15174892
Br J Clin Pharmacol. 2003 Dec;56(6):600-12
14616419
Int J Chron Obstruct Pulmon Dis. 2009;4:381-90
19888356
J Aerosol Med Pulm Drug Deliv. 2014 Apr;27(2):138-47
24004178
AAPS PharmSciTech. 2009;10(4):1252-62
19866362
Pharm Res. 2014 May;31(5):1239-53
24242939
Pharm Res. 2005 Sep;22(9):1445-53
16132356
J Pharm Sci. 2013 Oct;102(10):3736-47
23904207
J Pharm Sci. 2006 Jun;95(6):1382-92
16625656
Antimicrob Agents Chemother. 2013 Jun;57(6):2613-9
23529740
Pharm Res. 2008 May;25(5):999-1022
18040761
ISRN Allergy. 2013 Aug 05;2013:102418
23984095
Open Respir Med J. 2014 Jan 24;8:1-7
24570763
Pharm Res. 2005 Jun;22(6):923-32
15948036
Tuberculosis (Edinb). 2011 Jan;91(1):86-92
20888298
Vaccine. 2014 Nov 28;32(50):6791-7
25446830
Respir Care. 2005 Oct;50(10):1313-21; discussion 1321-2
16185367
Eur J Pharm Sci. 1998 Dec;7(1):73-80
9845780
Mol Pharm. 2015 Aug 3;12(8):2582-93
26052676
J Pharm Sci. 2014 May;103(5):1411-21
24585270
Multidiscip Respir Med. 2015 Apr 03;10(1):13
25878791
Pulm Pharmacol Ther. 2005;18(3):229-34
15707858
J Pharm Biomed Anal. 2010 Mar 11;51(4):853-7
19932579
Int J Pharm. 2008 Aug 6;360(1-2):1-11
18583072
Int J Clin Pract. 2004 May;58(5):444-50
15206499
J Aerosol Med. 1993 Summer;6(2):99-110
10146277
Drugs. 2013 Nov;73(16):1815-27
24194436
Expert Opin Drug Deliv. 2014 Mar;11(3):421-31
24397259
Pharm Res. 1999 Nov;16(11):1735-42
10571280